Medicine and Dentistry
Soft Tissue Sarcoma
100%
Neoplasm
76%
Surgery
56%
Connective Tissue Cancer
51%
Recurrent Disease
45%
Disease
42%
Malignant Neoplasm
38%
Liposarcoma
33%
Radiation Therapy
31%
Metastatic Carcinoma
27%
Overall Survival
23%
Retroperitoneal Sarcoma
23%
Chemotherapy
21%
Dedifferentiated Liposarcoma
20%
Leiomyosarcoma
19%
Prognostic Factor
16%
Survival Rate
15%
Desmoid Tumor
13%
Sarcoma Cell
13%
Protein P53
13%
Gastrointestinal Stromal Tumor
11%
Breast Cancer
11%
In Vitro
10%
Tumor Cell
10%
Disease Specific Survival
9%
Cancer
9%
Surgical Margin
8%
Disease Free Survival
8%
Malignant Peripheral Nerve Sheath Tumor
7%
Angiosarcoma
7%
Distant Metastasis
7%
Natural Killer Cell
7%
Imatinib
7%
Programmed Cell Death
7%
Cytotoxicity
6%
Well Differentiated Liposarcoma
6%
Doxorubicin
6%
Splenectomy
6%
External Beam Radiotherapy
6%
Limb
6%
Catenin
6%
Surgical Stress
5%
Preoperative Radiotherapy
5%
Xenograft
5%
Limb Tumor
5%
Recurrence Risk
5%
Biological Marker
5%
Tumor Progression
5%
Oncology
5%
Synovial Sarcoma
5%
Keyphrases
Soft Tissue Sarcoma
95%
Tumor
45%
Sarcoma
42%
Dedifferentiated Liposarcoma (DDLPS)
29%
Retroperitoneal Sarcoma
27%
Liposarcoma
26%
Resection
19%
Extremity Soft Tissue Sarcoma
18%
Local Recurrence
17%
Radiation Therapy
17%
Overall Survival
17%
Sarcoma Cells
17%
Leiomyosarcoma
16%
Gastrointestinal Stromal Tumor
16%
Surgical Resection
15%
Desmoid Tumor
15%
Chemotherapy
15%
Radiotherapy
15%
Prognostic Factors
14%
Metastasis
14%
Disease-specific Survival
11%
Retroperitoneal Liposarcoma
11%
Distant Metastasis
11%
Human Soft Tissue
10%
Malignant Peripheral Nerve Sheath Tumor (MPNST)
10%
Local Control
9%
Disease-free Survival
8%
Histological Subtypes
8%
Single Institution
8%
Well-differentiated
8%
Wild-type p53
8%
Doxorubicin
8%
Extracellular Vesicles
8%
Natural Killer Cells
8%
Tumor Size
8%
Breast
8%
Surgical Management
8%
Imatinib
8%
Confidence Interval
7%
Dedifferentiated
7%
Desmoid
7%
Breast Cancer
7%
Catenin
7%
Soft Tissue
7%
Tumor Cells
6%
Combined Modality Therapy
6%
Myxoid Liposarcoma
6%
Human Sarcoma
6%
Gross Total Resection
6%
High Risk
6%